Abstract
In the last decade a major advance in the treatment of breast cancer has been achieved with the introduction of antioestrogen therapy. The rationale behind this modality of treatment is to inhibit the peripheral action of oestrogens regardless of their circulating blood levels. This theoretically represents an advantage over endocrine ablative procedures which do not completely eliminate circulating oestrogens. It is the purpose of this paper to review the clinical use of the antioestrogen tamoxifen (Nolvadex®) in the management of advanced as well as early breast cancer. A summary will also be given on the use of tamoxifen in other malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 65-75 |
| Number of pages | 11 |
| Journal | Clinics in Oncology |
| Volume | 1 |
| Issue number | 1 |
| State | Published - Jan 1 1982 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Oncology
Cite this
}
Antiestrogens in tumor therapy. / Manni, A.; Pearson, O. H.
In: Clinics in Oncology, Vol. 1, No. 1, 01.01.1982, p. 65-75.Research output: Contribution to journal › Article
TY - JOUR
T1 - Antiestrogens in tumor therapy
AU - Manni, A.
AU - Pearson, O. H.
PY - 1982/1/1
Y1 - 1982/1/1
N2 - In the last decade a major advance in the treatment of breast cancer has been achieved with the introduction of antioestrogen therapy. The rationale behind this modality of treatment is to inhibit the peripheral action of oestrogens regardless of their circulating blood levels. This theoretically represents an advantage over endocrine ablative procedures which do not completely eliminate circulating oestrogens. It is the purpose of this paper to review the clinical use of the antioestrogen tamoxifen (Nolvadex®) in the management of advanced as well as early breast cancer. A summary will also be given on the use of tamoxifen in other malignancies.
AB - In the last decade a major advance in the treatment of breast cancer has been achieved with the introduction of antioestrogen therapy. The rationale behind this modality of treatment is to inhibit the peripheral action of oestrogens regardless of their circulating blood levels. This theoretically represents an advantage over endocrine ablative procedures which do not completely eliminate circulating oestrogens. It is the purpose of this paper to review the clinical use of the antioestrogen tamoxifen (Nolvadex®) in the management of advanced as well as early breast cancer. A summary will also be given on the use of tamoxifen in other malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0020356006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020356006&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0020356006
VL - 1
SP - 65
EP - 75
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
SN - 0889-8588
IS - 1
ER -